- MAY-262611
-
-
2026-06-30
- CAS:1123231-07-1
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
- WAY-262611
-
- $58.00
-
2026-04-20
- CAS:1123231-07-1
- Purity: 99.09%
- Supply Ability: 10g
- WAY-262611
-
-
2025-08-22
- CAS:1123231-07-1
- Min. Order: 10gram
- Purity: 99%
- Supply Ability: 20 tons
|
| | MAY-262611 Basic information |
| Product Name: | MAY-262611 | | Synonyms: | 1-[4-(2-Naphthalenyl)-2-pyrimidinyl]-4-piperidinemethanamine MAY-262611;MAY-262611;4-PiperidineMethanaMine, 1-[4-(2-naphthalenyl)-2-pyriMidinyl]-;1-[4-(2-Naphthalenyl)-2-pyrimidinyl]-4-piperidinemethanamine;1-{1-[4-(2-Naphthyl)-2-pyrimidinyl]-4-piperidinyl}methanamine;CS-1296;WAY262611; WAY 262611;Recombinant Human DKK-1/DKK1 Protein, 8* His Tag | | CAS: | 1123231-07-1 | | MF: | C20H22N4 | | MW: | 318.42 | | EINECS: | 604-604-1 | | Product Categories: | Inhibitors | | Mol File: | 1123231-07-1.mol |  |
| | MAY-262611 Chemical Properties |
| Boiling point | 544.8±42.0 °C(Predicted) | | density | 1.169±0.06 g/cm3(Predicted) | | storage temp. | under inert gas (nitrogen or Argon) at 2–8 °C | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 50 mg/ml; Ethanol:PBS (pH 7.2) (1:1): 0.5 mg/ml | | form | Powder | | pka | 10.13±0.29(Predicted) | | color | Light yellow to yellow |
| | MAY-262611 Usage And Synthesis |
| Uses | WAY-262611 is a Wnt/β-Catenin agonist that increases bone formation rate with an EC50 of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also a Dkk1 inhibitor[1]. | | Definition | ChEBI: [1-[4-(2-naphthalenyl)-2-pyrimidinyl]-4-piperidinyl]methanamine is a member of naphthalenes. | | in vivo | WAY-262611 has excellent pharmacokinetic properties and shows a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration. Calvariae from wt mice treated with WAY-262611 shows statistically increased BFR, while similarly treated KO animals are no different from control. This indicates that WAY-262611 is acting via the Wntβ-catenin pathway and most likely through inhibition of Dkk-1[1]. | | References | [1] Pelletier JC, et al. (1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: a wingless beta-catenin agonist that increases bone formation rate. J Med Chem. 2009 Nov 26;52(22):6962-5. DOI:10.1021/jm9014197
[2] L Enochson, et al. GDF5 reduces MMP13 expression in human chondrocytes via DKK1 mediated canonical Wnt signaling inhibition. Osteoarthritis Cartilage. 2014 Apr;22(4):566-77. DOI:10.1016/j.joca.2014.02.004 |
| | MAY-262611 Preparation Products And Raw materials |
|